Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.
Interferon beta-1a is available as an immunomodulating agent for relapsing forms of multiple sclerosis. Common side effects include flu-like symptoms, asthenia, anorexia, and administration site reaction. Kidney disorders are rarely reported. In this study we describe the case of a woman who has been undergoing treatment with interferon beta-1a for multiple sclerosis for 5 years. She developed a hemolytic-uremic syndrome with intravascular hemolysis in a context of severe hypertension. A kidney biopsy showed a thrombotic microangiopathy. This observation highlights an uncommon side effect of long-term interferon beta-1a therapy. Pathophysiological mechanisms leading to this complication might be explained by the antiangiogenic activity of interferon.
Clinical Pharmacology Department, Institute of Biology, University Hospital, Nantes, France. julien.mahe@chu-nantes.fr
Julien
J
Mahe
Aurélie
A
Meurette
Anne
A
Moreau
Caroline
C
Vercel
Pascale
P
Jolliet
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000328:Adult; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects*; D007674:Kidney Diseases / Q000139:chemically induced*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D057049:Thrombotic Microangiopathies / Q000139:chemically induced*
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a
antiangiogenic activity; hemolytic-uremic syndrome; interferon beta; thrombotic microangiopathy